Table 2 Adverse events experienced by those receiving full dose (n = 167) and reduced dose intensity of bevacizumab (n = 52)
Events secondary to bevacizumab | Full Dose Intensity (n = 167) | Reduced Dose Intensity (n = 52) | ||
|---|---|---|---|---|
Any Grade no. (%) | G3/4 no. (%) | Any Grade no. (%) | G3/4 no. (%) | |
Fatigue | 61 (37) | 0 (0) | 22 (42) | 1 (2) |
Hypertension | 26 (16) | 7 (4) | 11 (21) | 4 (8) |
Bleeding other sites* | 22 (13) | 0 (0) | 8 (16) | 0 (0) |
Proteinuria | 10 (6) | 4 (2) | 10 (19) | 1 (2) |
Variceal bleeding | 6 (4) | 4 (2) | 8 (15) | 6 (12) |
Mucositis | 5 (3) | 0 (0) | 8 (15) | 1 (2) |
Cardiac disease | 2 (1) | 0 (0) | 0 (0) | 0 (0) |
Thrombosis | 1 (0.6) | 0 (0) | 1 (2) | 0 (0) |
Events secondary to atezolizumab | ||||
MSK disorders | 22 (13) | 0 (0) | 6 (12) | 1 (2) |
Pruritis | 27 (16) | 0 (0) | 8 (15) | 1 (2) |
Rash | 19 (11) | 3 (2) | 8 (15) | 0 (0) |
Diarrhoea | 16 (10) | 4 (2) | 4 (8) | 0 (0) |
ALT derangement | 10 (6) | 1 (0.6) | 3 (6) | 0 (0) |
Hypothyroidism | 10 (6) | 0 (0) | 3 (6) | 0 (0) |
Hyperthyroidism | 7 (4) | 1 (0.6) | 1 (2) | 0 (0) |
Hepatitis | 4 (2) | 1 (0.6) | 1 (2) | 1 (2) |
Respiratory disorder | 2 (1) | 0 (0) | 0 (0) | 0 (0) |
Pancreatitis | 1 (0.6) | 0 (0) | 0 (0) | 0 (0) |
Pituitary dysfunction | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
Adrenal dysfunction | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
